)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Gland Pharma
Gland Pharma (GLAND) investor relations material
Gland Pharma Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary6 Nov, 2026
Executive summary
Q2 FY27 revenue was ₹18,335.88 million, up 23% YoY; adjusted EBITDA rose 50% to ₹5,030 million and PAT increased 58% to ₹2,907.56 million.
6M FY27 revenue grew 21% to ₹36,339 million; adjusted EBITDA reached ₹10,132 million, up 43%, and PAT was ₹6,077 million, up 52%.
Growth was led by CDMO, Critical Injectables and the US market, supported by launches, higher volumes and customer demand.
Financial highlights
Q2 gross profit was ₹11,638 million, up 25%, at a 63% margin; 6M gross profit was ₹23,397 million, up 22%, at a 64% margin.
Q2 EBITDA was ₹4,804 million, up 53%, at a 26% margin; adjusted EBITDA was ₹5,030 million at 27%, excluding ₹226 million of non-cash ESOP expense.
Q2 PBT rose 52% to ₹4,309 million; 6M PBT increased 45% to ₹8,659 million.
Q2 PAT margin was 16%, versus 12% a year earlier; 6M PAT margin was 17%, versus 13%.
Q2 R&D expense was ₹1,077 million, 6% of revenue, versus ₹817 million in Q2 FY26.
Outlook and guidance
FY27 revenue growth guidance remains 15% on a constant-currency basis; U.S. growth is expected to continue and ROW markets to improve.
Cenexi’s FY27 guidance remains EUR 200 million revenue at a high-single-digit margin; management said the lower Q2 result was included in its estimate.
Complex injectables remain a long-term growth focus; three additional in-house pipeline products are in line for approval.
Commercialization of 15 co-development products is anticipated from FY29; R&D spending may rise modestly as development shifts to more complex products.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Gland Pharma
- Income grew, profit declined, and Fosun’s 74% acquisition reshaped ownership.GLAND
Q4 17/18 - FY19 income grew 27.4%, led by exports, while ₹200 mn separation costs affected earnings.GLANDQ4 18/19
- FY20 export-led growth lifted revenue 28.81% and PAT 71.02%.GLANDQ4 19/20
- Revenue grew 32%, EBITDA margin reached 40%, and ROW revenue surged 136%.GLANDQ4 20/21
- Revenue grew 27% as capacity and product launches advanced despite cost and supply pressures.GLANDQ4 21/22
- FY23 earnings fell, while Cenexi expands European CDMO scale.GLANDQ4 22/23
- Revenue up 20% YoY, PAT up 47%, led by CDMO/B2B growth and strong US/Europe markets.GLANDQ1 26/27
- Q2 FY26 revenue up 6% YoY, PAT up 12%, led by US, Europe, and Cenexi growth.GLANDQ2 25/26
- Q3 FY25 revenue fell 10% YoY, but margins and new launches support future growth.GLANDQ3 24/25
Next Gland Pharma earnings date
Q3 26/2727 Jan, 2027
Gland Pharma
Next Gland Pharma earnings date
Q3 26/2727 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Gland Pharma Limited manufactures and markets injectable pharmaceutical products. Its product portfolio includes vials, pre-filled syringes, and infusion bags, primarily for hospital and clinical use. The company is headquartered in Hyderabad, India, and its shares are listed on the NSE.